Please assess the completion status of the following clinical trial:

Trial Title: Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Type 2 diabetes mellitus diagnosed at least 3 months with FPG level \<=240mg/dL and HbA1c between 6.5% and 10% inclusive.~* Must be diet controlled - OR - taking a single oral antidiabetic agent (other than thiazolidinediones) and willing to withdraw from this treatment from 2 weeks prior to the study.~* Must have a BMI:\<=35kg/m2, 20 to 70 years of age inclusive.~* Woman must be of non-childbearing potential.~Exclusion criteria:~* Positive test result for either syphilis, HBs antigen, HCV antibody, HIV antigen/antibody, or HTLV-1 antibody.~* Clinically significant hepatic enzyme elevation.~* History of metabolic disease other than T2DM.~* Previous use of insulin as a treatment for diabetes within 3 months.~* History of severe gastrointestinal disease.~* Clinically significant cardiovascular disease.~* Significant renal disease as defined by screening lab test.~* History of drug (including albumin or albumin containing agents) allergy.~* History of alcohol or drug abuse.~* Donation of blood in excess of 400mL within previous 4 months.~* Previously received any GLP-1 mimetic or any other albumin-containing products.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Subjects receiving GSK716155 + placebo (Type: EXPERIMENTAL): Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).